#China #Hangzhou #CellOrigin #ASCO2026 #Walvax

Exciting Developments from CellOrigin at ASCO 2026

The 2026 ASCO Annual Meeting has brought significant advancements in cancer treatment, particularly in the realm of solid tumors. CellOrigin, a biotechnology leader specializing in innovative cell therapy technologies, has made waves with the introduction of two novel therapy candidates, showcasing the forefront of research and collaboration in this critical field.

New Therapies Presented

At the forefront of CellOrigin's presentation were two promising studies showcasing revolutionary approaches to solid tumor treatment.

1. CAR-Mix™ Therapy

The first study detailed CAR-Mix™, a multicellular synergistic therapy that merges engineered macrophages with polyclonal T cells. This innovative combination demonstrated impressive antitumor efficacy in preclinical models of mesothelin-positive ovarian cancer. The therapy's design aims to address the challenge of antigen heterogeneity, which is a significant barrier in the treatment of solid tumors. Early clinical trial results, which commenced dosing patients earlier this year, reveal a well-tolerated safety profile and indications of clinical effectiveness.

2. TMT Engager™

The second advancement is the TMT Engager™, an LNP-mRNA-based T-cell engager that enables the formation of a tripartite complex involving T cells, macrophages, and tumor cells. This strategic engagement of both innate and adaptive immunity seeks to improve outcomes against a variety of tumor antigens, addressing the critical issue of treatment resistance linked to tumor heterogeneity. Preliminary findings from preclinical models, particularly focusing on liver and ovarian cancers, highlight the robust antitumor activities of this approach.

Strategic Partnership with Walvax

In addition to product advancements, CellOrigin has also announced a strategic partnership with Walvax Biotechnology. Together, they will co-develop an Investigator-Initiated Trial (IIT) aimed at treating hepatocellular carcinoma using the innovative mRNA-LNP-based GPC3-CAR therapy. This new trial builds on earlier findings presented at the 2025 ASCO meeting and leverages the combined strengths of both organizations: CellOrigin's expertise in precision CAR design and IIT execution and Walvax's capabilities in large-scale manufacturing and product registration.

Comprehensive CAR Technology Platform

CellOrigin's commitment to addressing solid tumors, autoimmune diseases, and organ fibrosis is evident in the establishment of a robust in vivo CAR technology platform. Through substantial R&D investments, the company has developed core capabilities that include:

• - mRNA-LNP Delivery Technology: This innovation allows for targeted in vivo CAR expression, optimizing efficacy while ensuring safety.
• - Advanced CAR Molecule Design: Focused on critical challenges, these designs aim for precise targeting of solid tumors and enhancing the durability of immune responses through memory T-cell formation.
• - Full-chain Translational Capability: Covering product design, clinical trial implementation, and regulatory approvals, this capability enables rapid development of therapies.

Commitment to Innovation

CellOrigin's strategic initiatives emphasize its leadership in the in vivo CAR therapy landscape for solid tumors. With a proprietary portfolio that includes iMAC™, CAR-Vac™, CAR-Mix™, and TMT Engager™, the company is poised to push the boundaries of immunocellular therapies. Looking towards the future, CellOrigin remains dedicated to scientific innovation and fostering collaborations within the industry, aimed at advancing cutting-edge immunotherapies to meet the pressing medical needs of patients.

For further details on the studies presented, interested parties can find the official ASCO publication links for the CAR-Mix and TMT Engager therapies to explore the data and findings.

As we progress into a new era of cancer treatment, CellOrigin's ongoing efforts may redefine the approach to solid tumors, paving the way for more effective therapies that tackle the challenges previously faced by oncologists worldwide.